Report cover image

U.S. CRISPR & Cas Genes Market Size, Share, Trends, Industry Analysis Report By Product (Kits & Enzymes, Libraries), By Service, By Application, By End Use – Market Forecast, 2025–2034

Published Sep 01, 2025
Length 129 Pages
SKU # PLRS20451529

Description

The U.S. crispr & cas genes market size is expected to reach USD 8.29 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. CRISPR & Cas Genes Market Size, Share, Trends, Industry Analysis Report By Product (Kits & Enzymes, Libraries), By Service, By Application, By End Use – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

CRISPR-Cas genes refer to a natural bacterial defense system used for gene editing. The CRISPR sequences guide the Cas enzyme to specific DNA locations to make precise cuts.

The U.S. has a well-established patent system that supports innovation and protects proprietary CRISPR technologies. Institutes such as the Broad Institute and the University of California have secured foundational CRISPR-Cas9 patents, creating a structured framework for licensing and commercialization. This robust IP environment encourages research institutions and biotech startups to invest confidently in CRISPR development. Furthermore, exclusive licensing deals and cross-licensing agreements are enabling new partnerships and accelerating product development. A strong legal infrastructure for protecting gene-editing innovations gives U.S. companies a competitive edge in both domestic and international markets.

Effective delivery of CRISPR components into human cells is crucial for successful gene editing, and U.S.-based researchers are leading in developing advanced delivery systems such as lipid nanoparticles, viral vectors, and electroporation methods. These innovations are improving the precision, efficiency, and safety of CRISPR-based interventions. Additionally, advancements in base editing and prime editing are opening new possibilities for correcting genetic mutations without double-stranded DNA breaks. This continuous evolution in gene-editing platforms improves the versatility and therapeutic potential of CRISPR in the U.S. market.

U.S. CRISPR & Cas Genes Market Report Highlights

The kits & enzymes segment is projected to register a CAGR of 19.1% over the forecast period, owing to their essential role in facilitating gene-editing processes.

The kits and enzymes segment is anticipated to register a CAGR of 19.3% during the forecast period, driven by the extensive adoption of gene-editing tools across academic and commercial research settings.

The contract research organizations (CROs) segment held a significant revenue share of 15.59% in 2024, as they continue to provide specialized CRISPR-related research services to pharmaceutical and biotechnology companies.

A few key players in the U.S. CRISPR & Cas genes market are Addgene, AstraZeneca, Caribou Biosciences, Inc., Cellectis, CRISPR Therapeutics, Danaher Corporation, Merck KGaA, Thermo Fisher Scientific, and Wellcome Trust Sanger Institute.

Polaris Market Research has segmented the U.S. CRISPR & Cas genes market report based on product, service, application, end use, and region:

By Product (Revenue - USD Billion, 2020–2034)

Kits & Enzymes

Vector-based Cas

DNA-free Cas

Libraries

Design Tool

Antibodies

Other Products

By Service (Revenue - USD Billion, 2020–2034)

Cell Line Engineering

gRNA Design

Microbial Gene Editing

DNA Synthesis

By Application (Revenue - USD Billion, 2020–2034)

Biomedical

Agricultural

By End Use (Revenue - USD Billion, 2020–2034)

Biotechnology & Pharmaceutical Companies

Academics & Government Research Institutes

Contract Research Organizations (CROs)

Table of Contents

129 Pages
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. U.S. Trade Finance Market Insights
4.1. U.S. Trade Finance Market – Market Snapshot
4.2. U.S. Trade Finance Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Growth in Global Trade Activities
4.2.1.2. Rise of Digitalization and Technology
4.2.2. Restraints and Challenges
4.2.2.1. Dependence on global trade cycles and economic uncertainties
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. U.S. Trade Finance Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. U.S. Trade Finance Market, by Instrument
5.1. Key Findings
5.2. Introduction
5.2.1. U.S. Trade Finance Market, by Instrument, 2020–2034 (USD Billion)
5.3. Letter of Credit
5.3.1. U.S. Trade Finance Market, by Letter of Credit, by Region, 2020–2034 (USD Billion)
5.4. Supply Chain Financing
5.4.1. U.S. Trade Finance Market, by Supply Chain Financing, by Region, 2020–2034 (USD Billion)
5.5. Documentary Collections
5.5.1. U.S. Trade Finance Market, by Documentary Collections, by Region, 2020–2034 (USD Billion)
5.6. Receivables Financing/Invoice Discounting
5.6.1. U.S. Trade Finance Market, by Receivables Financing/Invoice Discounting, by Region, 2020–2034 (USD Billion)
5.7. Others
5.7.1. U.S. Trade Finance Market, by Others, by Region, 2020–2034 (USD Billion)
6. U.S. Trade Finance Market, by Service Provider
6.1. Key Findings
6.2. Introduction
6.2.1. U.S. Trade Finance Market, by Service Provider, 2020–2034 (USD Billion)
6.3. Banks
6.3.1. U.S. Trade Finance Market, by Banks, by Region, 2020–2034 (USD Billion)
6.4. Financial Institutions
6.4.1. U.S. Trade Finance Market, by Financial Institutions, by Region, 2020–2034 (USD Billion)
6.5. Trading Houses
6.5.1. U.S. Trade Finance Market, by Trading Houses, by Region, 2020–2034 (USD Billion)
6.6. Others
6.6.1. U.S. Trade Finance Market, by Others, by Region, 2020–2034 (USD Billion)
7. U.S. Trade Finance Market, by Trade
7.1. Key Findings
7.2. Introduction
7.2.1. U.S. Trade Finance Market, by Trade, 2020–2034 (USD Billion)
7.3. Domestic
7.3.1. U.S. Trade Finance Market, by Domestic, by Region, 2020–2034 (USD Billion)
7.4. International
7.4.1. U.S. Trade Finance Market, by International, by Region, 2020–2034 (USD Billion)
8. U.S. Trade Finance Market, by Industry
8.1. Key Findings
8.2. Introduction
8.2.1. U.S. Trade Finance Market, by Industry, 2020–2034 (USD Billion)
8.3. BFSI
8.3.1. U.S. Trade Finance Market, by BFSI, by Region, 2020–2034 (USD Billion)
8.4. Construction
8.4.1. U.S. Trade Finance Market, by Construction, by Region, 2020–2034 (USD Billion)
8.5. Wholesale/Retail
8.5.1. U.S. Trade Finance Market, by Wholesale/Retail, by Region, 2020–2034 (USD Billion)
8.6. Manufacturing
8.6.1. U.S. Trade Finance Market, by Manufacturing, by Region, 2020–2034 (USD Billion)
8.7. Automobile
8.7.1. U.S. Trade Finance Market, by Automobile, by Region, 2020–2034 (USD Billion)
8.8. Shipping & Logistics
8.8.1. U.S. Trade Finance Market, by Shipping & Logistics, by Region, 2020–2034 (USD Billion)
8.9. Others
8.9.1. U.S. Trade Finance Market, by Others, by Region, 2020–2034 (USD Billion)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. Bank of America Corporation
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. BNP Paribas SA
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. Citigroup Inc.
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. Deutsche Bank AG
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. HSBC Holdings plc
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. JPMorgan Chase & Co.
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. Standard Chartered Bank
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. The PNC Financial Services Group, Inc.
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. U.S. Bank
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. Wells Fargo & Company
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.